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Abstract The 894G>T single nucleotide polymorphism
(SNP) in the endothelial NOS (NOS3) gene, has recently
been associated with embryonic spina biﬁda risk. In this
study, a possible association between the NOS3 894G>T
SNP and spina biﬁda risk in both mothers and children in a
Dutch population was examined using both a case-control
design and a transmission disequilibrium test (TDT). Pos-
sible interactions between the NOS3 894G>T SNP and the
MTHFR 677C>T SNP, elevated plasma homocysteine, and
decreased plasma folate concentrations were also studied.
The NOS3 894TT genotype did not increase spina biﬁda
risk in mothers or children (OR 1.50, 95%CI 0.71–3.19 and
OR 1.78, 95%CI 0.75–4.25, respectively). The TDT dem-
onstrated no preferential transmission of the NOS3 894T
allele (C
2 = 0.06, P = 0.81). In combination with the
MTHFR 677TT genotype or elevated plasma homocysteine
concentrations, the NOS3 894GT/TT genotype increased
maternal spina biﬁda risk (OR 4.52, 95%CI 1.55–13.22 and
OR 3.38, 95%CI 1.46–7.84, respectively). In our study
population, the NOS3 894GT/TT genotype might be a risk
factor for having a spina biﬁda affected child in mothers
who already have an impaired homocysteine metabolism.
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Introduction
Nitric oxide synthase (NOS) catalyzes the generation of
nitric oxide (NO), an important signaling molecule that
mediates many of its biological effects by activating the
enzyme guanylyl cyclase, thereby increasing cyclic GMP
synthesis (Murad 2006). Besides its important role in car-
diovascular control, NO has been suggested to play a role
in development (Lee and Juchau 1994). NO has been
demonstrated to be present in the neural tube of chick
embryos at the time of neurulation (Traister et al. 2002)
and regulates the balance between mitosis and programmed
cell death (Plachta et al. 2003). Other studies show that NO
can inhibit methionine synthase (MTR) enzyme activity,
thereby interfering with homocysteine remethylation
(Danishpajooh et al. 2001) and proper neurulation (Nach-
many et al. 2006; Weil et al. 2004).
The 894G>T single nucleotide polymorphism (SNP) in
the endothelial-derived nitric oxide synthase (NOS3) gene,
identiﬁed by Hingorani et al. (1999), was shown to be
associated with elevated plasma homocysteine levels in
nonsmokers with low serum folate concentrations (Brown
et al. 2003). More recently, it was demonstrated that the
NOS3 894GT genotype is an embryonic risk factor for
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2004).
In this study, we examined the relation between the
NOS3 894G>T SNP and spina biﬁda risk in both mothers
and children using a case-control design and a transmission
disequilibrium test (TDT). An effect of the NOS3 894G>T
SNP on plasma homocysteine or plasma folate concentra-
tion was examined as well as possible interactions between
the NOS3 894G>T SNP and the MTHFR 677C>T SNP,
elevated plasma homocysteine, and decreased plasma fo-
late concentrations.
Materials and methods
Study population
The study population has been described in detail before
(van der Linden et al. 2006). Brieﬂy, the study population
was recruited in collaboration with the BOSK and was
extended by a group from the Pediatric Neurology
Department of the Radboud University Nijmegen Medical
Center. The study group included 109 spina biﬁda patients
(61 girls and 48 boys, mean age 16.4 ± 11.3), their mothers
(n = 121, mean age 42.9 ± 10.9) and fathers (n = 103,
mean age 44.9 ± 10.2).
The control group consisted of 500 volunteers recruited
from a general practice in The Hague (den Heijer et al.
1995). In the present study we only included the 292 wo-
men from this control group (mean age 50.6 ± 13.5). The
pediatric control group included 234 children (119 girls
and 115 boys, mean age 8.4 ± 6.4) (van Beynum et al.
1999). The children of secondary school age were healthy
volunteers, and the younger children were, for ethical
reasons, recruited in a hospital setting. The local medical
ethics committee approved the study.
For the present study, DNA of 102 spina biﬁda patients,
116 mothers, 101 fathers, 265 control women and 211
pediatric controls was available for genotyping.
Biochemical determinations
Plasma total homocysteine concentration was measured in
EDTA plasma by HPLC and ﬂuorescence detection, as
previously described by te Poele-Pothoff et al. (1995).
Plasma folate concentration was determined using the
Dualcount Solid Phase Boil Radio assay (Diagnostic
Product Corporation, Los Angeles, CA).
PCR ampliﬁcation and genotype determination
NOS3 894G>T genotyping was performed according to
Hingorani et al. (1999). Primer annealing took place at a
temperature of 58 C. The PCR product of 206 bp was cut
with the restriction enzyme MboI, which cuts the T allele in
fragments of 119 and 87 bp.
Statistical analyses
Case-control study
Odds ratios (ORs) and their 95% conﬁdence intervals
(95%CI) were calculated by means of logistic regression
analysis.
The effect of the NOS3 894G>T SNP on plasma hom-
ocysteine and plasma folate concentration was studied by
means of linear regression analysis. Since the distributions
of plasma homocysteine and plasma folate concentrations
are positively skewed, these variables were logarithmically
transformed prior to linear regression analysis.
Deviation from Hardy–Weinberg equilibrium was cal-
culated to assess the accuracy of the genotyping assay.
The power of the case-control study was calculated
using the Genetic Power Calculator (Purcell et al. 2003).
All tests were performed using SPSS software package
version 12.0.1. Statistical signiﬁcance was accepted at a
two-tailed P < 0.05 or 95%CI of an odds ratio that did not
include 1.0.
Transmission disequilibrium test
The relation between the NOS3 894G>T genotype of the
spina biﬁda patients and spina biﬁda risk was assessed by
evaluating the transmission of alleles from heterozygous
parents to their affected offspring using the TDT, a family-
based association test (Spielman et al. 1993). The power of
the TDT was calculated using the Genetic Power Calcu-
lator (Purcell et al. 2003).
Results
Case-control study
The NOS3 894G>T genotype could be determined in 115
mothers of a spina biﬁda affected child and in 259 female
controls. Genotype distribution did not differ from that
expected under Hardy–Weinberg equilibrium (P = 0.83),
and the power to detect a twofold increase in maternal
spina biﬁda risk was 59%. Table 1 demonstrates that nei-
ther the NOS3 894GT genotype nor the NOS3 894TT
genotype increased maternal spina biﬁda risk relative to the
NOS3 894GG genotype. Since the effect of the NOS3
894GT genotype and the NOS3 894TT genotype on spina
biﬁda risk was the same relative to the NOS3 894GG
genotype, the NOS3 894GT and TT genotypes were
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123combined to increase power, which resulted in a nonsig-
niﬁcant 36% increased risk of having a spina biﬁda af-
fected child relative to the NOS3 894GG genotype (OR
1.36, 95%CI 0.87–2.11). The NOS3 894G>T SNP was not
associated with plasma homocysteine or plasma folate
concentrations in mothers and female controls (data not
shown).
In 95 spina biﬁda patients and 207 pediatric controls,
NOS3 894G>T genotyping was performed successfully.
The NOS3 894G>T genotype distribution did not differ
from that expected under Hardy–Weinberg equilibrium
(P = 0.76), and the power of the study was 51%. The NOS3
894GT genotype increased spina biﬁda risk in children
whereas the NOS3 894TT genotype did not (Table 2).
Combining the NOS3 894GT and 894TT genotypes re-
sulted in a 66% increase in spina biﬁda risk relative to the
NOS3 894GG genotype (OR 1.66, 95%CI 1.02–2.72). In
the pediatric controls, the NOS3 894GT and 894TT geno-
types were associated with increased plasma homocysteine
concentrations relative to the NOS3 894GG genotype
(14.7% increase, 95%CI 4.2–26.2% and 23.5% increase,
95%CI 3.9–46.8%, respectively). There was no association
between the NOS3 894G>T SNP and plasma folate con-
centration in children (data not shown).
Transmission disequilibrium test
In this study there were 75 complete mother–father–child
triads, and the power to detect a twofold increase in spina
biﬁda risk was 32%. In 36 out of 70 informative trans-
missions (51.4%), the NOS3 894T allele was transmitted to
the child, which resulted in a C
2 of 0.06 (P = 0.81).
Gene-gene interaction
Data on both the NOS3 894G>T genotype and the MTHFR
677C>T genotype were present for 110 mothers of a spina
biﬁda affected child and 259 control women. Since the
MTHFR 677CT genotype did not increase spina biﬁda risk
relative to the MTHFR 677CC genotype, we decided to
combine the MTHFR 677CC and CT genotypes to increase
power. In combination with the MTHFR 677TT genotype,
the NOS3 894GT/TT genotype increased the risk of having
spina biﬁda affected offspring 4.5 times relative to the
NOS3 894GG genotype combined with the MTHFR
677CC/CT genotype (OR 4.52, 95%CI 1.55–13.22) (Ta-
ble 3).
In children, there was no interaction between the NOS3
894GT/TT genotype and the MTHFR 677TT genotype (OR
1.23, 95%CI 0.31–4.91) (data not shown).
Gene-metabolite interactions
Since the MTHFR 677C>T SNP is a genetic determinant of
plasma folate and plasma homocysteine concentrations,
possible interactions between the NOS3 894G>T SNP and
these metabolites were examined in mothers. In combina-
tion with decreased plasma folate concentrations
(<8.52 nmol/L), the NOS3 894GT/TT genotype did not
increase maternal spina biﬁda risk relative to the NOS3
894GG genotype in combination with normal plasma folate
concentrations (‡8.52 nmol/L) (OR 1.14, 95%CI 0.49–
2.67) (data not shown). The risk of having spina biﬁda
affected offspring increased to 3.4-fold when the NOS3
894GT/TT genotype was present in combination with
elevated plasma homocysteine concentrations (‡12.56
lmol/L) (OR 3.38, 95%CI 1.46–7.84) (Table 4).
Discussion
Inthisstudy,theNOS3894TTgenotypedidnotsigniﬁcantly
increase spina biﬁda risk, and the TDT demonstrated no
preferentialtransmissionoftheNOS3894Tallele.However,
in combination with the MTHFR 677TT genotype or
Table 1 The NOS3 894G>T genotype distribution and unadjusted
ORs in mothers of a spina biﬁda affected child and female controls
NOS3
894G>T
Mothers (%) Female
controls (%)
OR (95%CI)
GG 49 (42.6) 130 (50.2) 1
a
GT 53 (46.1) 106 (40.9) 1.33 (0.83–2.11)
TT 13 (11.3) 23 (8.9) 1.50 (0.71–3.19)
a Reference group
Table 2 The NOS3 894G>T genotype distribution and unadjusted
ORs in spina biﬁda patients and pediatric controls
NOS3
894G>T
SB patients (%) Pediatric
controls (%)
OR (95%CI)
GG 39 (41.1) 111 (53.6) 1
a
GT 46 (48.4) 80 (38.6) 1.64 (0.98–2.74)
TT 10 (10.5) 16 (7.7) 1.78 (0.75–4.25)
a Reference group
Table 3 Maternal spina biﬁda risk for the combination of the NOS3
894G>T SNP and the MTHFR 677C>T SNP
NOS3
894G>T
MTHFR
677C>T
Mothers (%) Female
controls (%)
OR (95%CI)
GG CC/CT 42 (38.2) 114 (44.0) 1
a
GG TT 6 (5.5) 16 (6.2) 1.02 (0.37–2.77)
GT/TT CC/CT 52 (47.3) 123 (47.5) 1.15 (0.71–1.85)
GT/TT TT 10 (9.1) 6 (2.3) 4.52 (1.55–13.22)
a Reference group
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123elevated plasma homocysteine concentrations, the NOS3
894GT/TT genotype increased maternal spina biﬁda risk
4.5- and 3.4-fold, respectively.
Using a likelihood ratio test (LRT) for both proband and
mother trios, Brown et al. (2004) demonstrated the NOS3
894GT genotype, but not the NOS3 894TT genotype, to be
an embryonic risk factor for spina biﬁda (OR 1.63, 95%CI
1.09–2.42). Data from our case-control study might be in
line with this observation of Brown et al. (2004); however,
based on the effect of the heterozygous NOS3 894GT
genotype on spina biﬁda risk, a larger effect of the NOS3
894TT genotype on spina biﬁda risk would be expected.
The observation that the NOS3 894GT genotype increases
spina biﬁda risk and the NOS3 894TT genotype does not
could be explained as a chance ﬁnding, but could also be
the result of lack of power, as also suggested by Brown
et al. (2004).
Despite the small numbers on which the analyses are
based, the possible interactions between the NOS3 894GT/
TT genotype and the MTHFR 677TT genotype or elevated
plasma homocysteine concentrations are interesting and
may suggest a role for NOS3 uncoupling or S-nitrosation.
The NOS3 894G>T SNP (Glu298Asp) has been suggested
to impair NOS3 protein function and/or activity resulting in
decreased NO production (Sofowora et al. 2001; Tesauro
et al. 2000), although results are contradictory (Fairchild
et al. 2001). Elevated homocysteine concentrations have
been demonstrated to switch the NOS3 enzyme to an
uncoupled state directed to the synthesis of reactive oxygen
species (ROS) rather than NO synthesis (Topal et al. 2004).
The combination of the NOS3 894GT/TT genotype and
elevated plasma homocysteine concentrations may lead to
such a decrease in NO levels that neurulation is hampered.
NO can also react with homocysteine to form S-nitroso-
thiols, thereby modulating homocysteine availability
(Stamler et al. 1993). As previously suggested by our group
(Heil et al. 2004), decreased NO levels may result in
decreased S-nitrosothiol formation, resulting in less cap-
turing of homocysteine into S-nitrosoHcy. The subsequent
increase in plasma homocysteine concentrations might
inﬂuence proper neural tube closure, especially when
plasma homocysteine concentrations are already high.
The results of our study suggest that the NOS3 894G>T
SNP is a spina biﬁda risk factor in the mother and not in the
child. Our results furthermore indicate a role for the
homocysteine metabolism in the detrimental effects as-
serted by the NOS3 894G>T SNP. More studies on the
association between the NOS3 894G>T SNP and spina
biﬁda in larger populations are warranted.
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